Advertisement
BBC vs XBI
Which ETF would AI Choose? Virtus Biotech Clinical Trials ETF (BBC) vs. State Street SPDR S&P Biotech ETF (XBI)
Key Takeaways
- Virtus Biotech Clinical Trials ETF (BBC) targets early-stage biotechnology companies with lead drug candidates in clinical trials, resulting in a narrower, higher-risk exposure compared to the broader approach of State Street SPDR S&P Biotech ETF (XBI).
- XBI employs an equal-weighted methodology across approximately 160 holdings in the S&P Biotechnology Select Industry Index, providing more balanced diversification within the biotech sector than BBC’s roughly 130 holdings focused exclusively on clinical-stage firms.
- BBC carries a higher expense ratio of 0.65% versus XBI’s 0.35%, reflecting its specialized thematic strategy versus XBI’s broader passive index tracking.
- Both ETFs operate as passive vehicles in the healthcare biotechnology space but differ in risk profile, with BBC emphasizing pre-approval clinical development stages and XBI including a mix of development-stage and commercial-stage companies.
- XBI offers greater liquidity and scale due to its larger asset base and longer track record since 2006, while BBC, launched in 2014, suits investors seeking targeted exposure to clinical trial outcomes.
- In recent market cycles, relative performance between the two has been driven by sector rotation within biotechnology, clinical trial news flow, and broader healthcare regulatory developments.
Introduction
Investors evaluating biotechnology exposure often compare specialized thematic funds with broader sector peers. Virtus Biotech Clinical Trials ETF (BBC) and State Street SPDR S&P Biotech ETF (XBI) both provide access to U.S. biotechnology equities yet pursue distinct strategies within the same industry. BBC focuses narrowly on companies with lead products in clinical development stages, while XBI delivers equal-weighted exposure across the wider biotechnology segment. This comparison highlights structural differences that matter for portfolio construction, risk tolerance, and thematic positioning in the current healthcare environment.
Virtus Biotech Clinical Trials ETF (BBC) Overview
Virtus Biotech Clinical Trials ETF (BBC) seeks to track the LifeSci Biotechnology Clinical Trials Index. The fund invests at least 80% of assets in U.S. exchange-listed biotechnology companies whose primary product offering, or lead drug, is typically in Phase 1, Phase 2, or Phase 3 clinical trials but has not yet received marketing approval. The strategy results in approximately 125 to 130 holdings concentrated on early-stage clinical development. Top holdings generally include smaller clinical-stage firms such as Kodiak Sciences Inc., AbCellera Biologics Inc., and Xencor Inc. Sector allocation is overwhelmingly healthcare biotechnology, with equal or modified weighting that emphasizes smaller-capitalization names. The expense ratio stands at 0.65%. BBC operates as a passive, rules-based thematic ETF with annual rebalancing aligned to the underlying index methodology.
State Street SPDR S&P Biotech ETF (XBI) Overview
State Street SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index, which represents the biotechnology segment of the S&P Total Market Index. The fund employs a sampling strategy and invests substantially all assets in index constituents. It holds approximately 160 to 165 stocks on an equal-weighted basis, spanning development-stage and commercial-stage biotechnology companies. Representative top holdings include Moderna Inc., Twist Bioscience Corp., Natera Inc., Amgen Inc., and Biogen Inc. The portfolio remains almost entirely within healthcare biotechnology. XBI maintains an expense ratio of 0.35% and follows a passive, equal-weighted approach with quarterly index rebalancing. The structure supports broad participation across market capitalizations within the sector.
Industry and Thematic Backdrop
The biotechnology sector operates within healthcare and remains sensitive to clinical trial results, regulatory approvals, interest rate expectations, and capital availability for research and development. Recent market cycles have featured rotation between large-cap commercial products and smaller development-stage assets, influenced by Food and Drug Administration guidance, merger and acquisition activity, and macroeconomic factors affecting growth-oriented equities. Both ETFs face risks from binary clinical outcomes, patent expirations, and competitive pressures, yet they capture different segments of innovation pipelines. Capital flows into biotechnology often accelerate during periods of favorable regulatory sentiment or breakthrough therapy designations.
Performance and Positioning Comparison
In recent weeks and months, performance differentials between Virtus Biotech Clinical Trials ETF (BBC) and State Street SPDR S&P Biotech ETF (XBI) have reflected varying sensitivity to clinical news flow and broader sector momentum. XBI’s inclusion of more established names has historically moderated volatility relative to BBC’s concentration in earlier-stage assets, which can experience sharper moves on trial data releases. During periods of sector rotation favoring commercial-stage products, XBI has tended to show more stable relative positioning, while BBC’s thematic focus amplifies exposure to pipeline catalysts. Both funds exhibit higher volatility than broad market benchmarks due to the inherent risks of biotechnology development.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into ETFs like BBC and XBI may find the platform useful for ongoing monitoring.
Tickeron AI Verdict
Based on observable structural factors including lower expense ratio, greater diversification across holdings, stronger liquidity profile, and broader participation in the biotechnology sector, Tickeron’s AI would currently assign a higher probability of favorability to State Street SPDR S&P Biotech ETF (XBI) for most investors seeking balanced exposure. BBC offers a more specialized clinical-trials focus that may appeal in targeted thematic allocations but carries elevated cost and concentration considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBC is a Hold and XBI is a StrongBuy.
BBC in -2.04% downward trend, falling for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BBC declined for three days, in 246 of 273 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Aroon Indicator for BBC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BBC's RSI Indicator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BBC as a result. In 66 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for BBC just turned positive on October 21, 2026. Looking at past instances where BBC's MACD turned positive, the stock continued to rise in 43 of 47 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBC advanced for three days, in 276 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
BBC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Momentum Indicator for XBI turns positive, indicating new upward trend
XBI saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 85 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XBI just turned positive on October 21, 2026. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in 49 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Following a +1.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
XBI moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| BBC | XBI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 4 days ago 90% | 3 days ago 90% |
| Declines ODDS (%) | 2 days ago 90% | 9 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Advertisement
BBC and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBC has been loosely correlated with RCUS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if BBC jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To BBC | 1D Price Change % | ||
|---|---|---|---|---|
| BBC | 100% | -1.94% | ||
| RCUS - BBC | 58% Loosely correlated | -2.26% | ||
| ANRO - BBC | 54% Loosely correlated | -3.71% | ||
| BHVN - BBC | 48% Loosely correlated | -6.49% | ||
| NUVB - BBC | 44% Loosely correlated | -0.21% | ||
| CATX - BBC | 41% Loosely correlated | -1.71% | ||
More | ||||
XBI and
Correlation & Price change
A.I.dvisor indicates that over the last year, XBI has been loosely correlated with VYGR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then VYGR could also see price increases.
| Ticker / NAME | Correlation To XBI | 1D Price Change % | ||
|---|---|---|---|---|
| XBI | 100% | -1.15% | ||
| VYGR - XBI | 59% Loosely correlated | -2.27% | ||
| LYEL - XBI | 57% Loosely correlated | -2.34% | ||
| RCUS - XBI | 57% Loosely correlated | -2.26% | ||
| LGND - XBI | 56% Loosely correlated | +1.71% | ||
| MGNX - XBI | 55% Loosely correlated | +0.84% | ||
More | ||||